SOPH · SOPHiA GENETICS S.A.

SOPHiA GENETICS delivered strong Q1 2026 results with revenue growth of 22% year-over-year to $21.7 million, driven by a record 108,000 genomic analyses (up 16% YoY) and robust demand across regions, including 28% U.S. analysis volume growth and 30% EMEA revenue increase. Gross margin held steady at 68.0% reported (75.4% adjusted), reflecting optimized compute costs and platform scale, while operating loss widened slightly to $17.3 million due to higher R&D, sales/marketing, and G&A expenses, including $0.7 million net legal costs from Guardant Health litigation. Net loss increased 11% to $19.3 million, primarily from elevated interest expense of $1.7 million. Balance sheet remains solid with $65.4 million in cash, down from $70.3 million at year-end amid $15.1 million operating cash burn, partially offset by $14.5 million from ATM offering. Management highlights Net Dollar Retention of 117%, 18 new core genomic customers, and expansions like Mount Sinai and CHU Bordeaux, signaling momentum in U.S. and new applications such as Liquid Biopsy (nearly 3,000 analyses, 100%+ YoY growth). Strategic partnerships, including MD Anderson collaboration, and BioPharma revenue growth support scalability. The company reaffirmed FY2026 guidance of $92-94 million revenue (20-22% growth) and $29-32 million Adjusted EBITDA loss, targeting breakeven by end-2026 and positive in H2 2027, underpinned by operational excellence and cost actions in April.